THERAVANCE BIOPHARMA, INC. (TBPH) Shareholders’ equity 2016–2025
THERAVANCE BIOPHARMA, INC. (TBPH) shareholders’ equity at each fiscal year-end, per SEC filings.
$296.7MFY2025 · since FY2016: $350.2M → $296.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $296.7M | +69.0% |
| FY2024 | $175.5M | -17.6% |
| FY2023 | $213.0M | -51.8% |
| FY2022 | $441.8M | +230.5% |
| FY2021 | -$338.6M | -11.5% |
| FY2020 | -$303.8M | -35.7% |
| FY2019 | -$223.8M | -333.9% |
| FY2018 | -$51.6M | -144.8% |
| FY2017 | $115.2M | -67.1% |
| FY2016 | $350.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice